HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25+ /CD54+ NK cells.

Abstract
Inadequate persistence of tumor-infiltrating natural killer (NK) cells is associated with poor prognosis in cancer patients. The solid tumor microenvironment is characterized by the presence of immunosuppressive factors, including prostaglandin E2 (PGE2), that limit NK cell persistence. Here, we investigate if the modulation of the cytokine environment in lung cancer with IL-2 or IL-15 renders NK cells resistant to suppression by PGE2. Analyzing Cancer Genome Atlas (TCGA) data, we found that high NK cell gene signatures correlate with significantly improved overall survival in patients with high levels of the prostaglandin E synthase (PTGES). In vitro, IL-15, in contrast to IL-2, enriches for CD25+ /CD54+ NK cells with superior mTOR activity and increased expression of the cAMP hydrolyzing enzyme phosphodiesterase 4A (PDE4A). Consequently, this distinct population of NK cells maintains their function in the presence of PGE2 and shows an increased ability to infiltrate lung adenocarcinoma tumors in vitro and in vivo. Thus, strategies to enrich CD25+ /CD54+ NK cells for adoptive cell therapy should be considered.
AuthorsZiqing Chen, Ying Yang, Shi Y Neo, Hao Shi, Yi Chen, Arnika K Wagner, Karin Larsson, Le Tong, Per-Johan Jakobsson, Evren Alici, Jing Wu, Yihai Cao, Kai Wang, Lisa L Liu, Yumeng Mao, Dhifaf Sarhan, Andreas Lundqvist
JournalEMBO reports (EMBO Rep) Vol. 22 Issue 3 Pg. e51329 (03 03 2021) ISSN: 1469-3178 [Electronic] England
PMID33480074 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2021 The Authors. Published under the terms of the CC BY 4.0 license.
Chemical References
  • Cytokines
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • Dinoprostone
Topics
  • Cyclic Nucleotide Phosphodiesterases, Type 4 (genetics)
  • Cytokines
  • Dinoprostone
  • Humans
  • Killer Cells, Natural
  • Signal Transduction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: